

AUDITED  
**2020**  
FINANCIAL REPORT

**Evonik Finance B.V.**  
Amsterdam

## Contents

<b>DIRECTORS' REPORT</b>	<b>3</b>
<b>FINANCIAL STATEMENTS</b>	<b>10</b>
1 Balance sheet as at December 31, 2020 (after appropriation of result)	11
2 Income statement for the year ended December 31, 2020	13
3 Cash flow statement for the year ended December 31, 2020	14
4 General information	15
5 Accounting policies for the balance sheet	17
6 Accounting policies for the income statement	21
7 Financial instruments and risk management	22
8 Notes to the balance sheet as at December 31, 2020	24
9 Notes to the income statement for the year ended December 31, 2020	32
<b>OTHER INFORMATION</b>	<b>36</b>
8 <b>INDEPENDENT AUDITOR'S REPORT</b>	<b>37</b>

## DIRECTORS' REPORT

### Annual Report 2020 of Board of Directors

We herewith report you on the exercise of our mandate over the financial year, ending by December 31, 2020 and present you the annual accounts of Evonik Finance B.V. Our 2020 financial statements have been audited by an independent external auditor.

**Evonik Finance B.V. domiciled in Amsterdam, the Netherlands** is a 100% subsidiary company of Evonik Industries AG (also referred to herein as 'Evonik'), based in Germany with operations throughout the world.

Evonik is one of the world's leading specialty chemicals companies. Our strengths include the balanced spectrum of our business activities, end-markets, and regions. Around 80 percent of sales come from **market-leading positions**<sup>1</sup>, which we are systematically expanding. Our strong competitive position is based on close collaboration with customers, high innovative capability, and integrated technology platforms.

Our specialty chemicals products make an indispensable contribution to the benefits of our customers' products, which generate their success in global competition. Close cooperation with our customers enables us to build up a **deep knowledge** of their business, so we can offer products tailored to their specifications and extensive technical service. Our technology centers and customer competence centers play an important role in this around the world.

Market-oriented research and development is an important driver of profitable growth. This is based on our strong **innovation culture**, which is rooted in our innovation management and management development. Good ideas are rapidly recognized, driven forward, and implemented with our customers.

### New corporate structure

Effective July 1, 2020, Evonik introduced a new **corporate structure**. The specialty chemicals operations are divided into four chemical manufacturing divisions, which operate close to their markets and customers. The new chemicals divisions—Specialty Additives, Nutrition & Care, Smart Materials, and Performance Materials—are more balanced in terms of size and profitability. Moreover, clearer alignment to the technology platforms allows more selective management. They are supported by the services operations.

#### Corporate structure effective July 1, 2020

Evonik				
Specialty Additives	Nutrition & Care	Smart Materials	Performance Materials	Services
A broad spectrum of additives and crosslinkers and formulating expertise that make the key difference for customers in growth markets such as coatings, mobility, infrastructure, and consumer goods.	Sustainable solutions for basic human needs for resilient end-markets such as pharmaceuticals, personal care, and animal nutrition.	Innovative materials that enable resource-efficient solutions and replace conventional materials. They are the smart answer to the major challenges of our time: the environment, urbanization, energy efficiency, mobility, and health.	Efficient technology platforms for the production of high-volume intermediates for mobility and the plastics and rubber industries as well as superabsorbents for consumer applications.	Site services and group-wide administrative, operational, and technical services.

<sup>1</sup> Evonik defines these as ranking 1st, 2nd, or 3rd in the relevant markets. Source: Internal evaluations based on 2019.

The Specialty Additives, Nutrition & Care, and Smart Materials divisions operate principally in attractive markets with above-average growth rates. These three divisions offer customers customized, innovation-driven solutions and the aim is for them to achieve above-average, profitable growth through innovations, investments, and acquisitions.

The Performance Materials division is characterized by processes that make intensive use of energy and raw materials. It therefore concentrates on integrated, cost-optimized technology platforms, efficient workflows, and economies of scale. Evonik's strategic goal for this division is to contribute earnings to finance the growth of the Evonik Group. Investments and, where appropriate, alliances concentrate on securing Evonik's good market positions.

<b>Key Figures Evonik Finance B.V.</b>		
<b>Overview</b>		
<b>in €</b>	<b>2020</b>	<b>2019</b>
<b>Operating result</b>	<b>-224.883</b>	<b>-543.634</b>
<b>Financial result</b>	<b>3.299.528</b>	<b>1.855.942</b>
<b>Profit/loss of financial year</b>	<b>2.322.984</b>	<b>-1.280.375</b>
<b>As at</b>	<b>31-12-2020</b>	<b>31-12-2019</b>
<b>Financial fixed assets</b>	<b>998.599.557</b>	<b>1.493.453.325</b>
<b>Current assets</b>	<b>532.538.390</b>	<b>655.656.359</b>
<b>Equity</b>	<b>246.979.497</b>	<b>244.480.892</b>
<b>Non-current liabilities</b>	<b>1.242.655.516</b>	<b>1.892.444.599</b>
<b>Current liabilities</b>	<b>41.502.934</b>	<b>12.184.193</b>

Evonik Finance B.V. was founded on 15 December 2010 with an authorized share capital of €250.000 (paid in €50.000).

The main objects of the company are;

- (a) to grant loans to foreign subsidiaries and joint ventures;
- (b) to issue loans and bonds;
- (c) to grant finance to group companies and guarantees to external parties securing group obligations.

## Income Statement Evonik Finance B.V.

### Overview

in €	2020	2019
- Operating expenses	-224.883	-543.634
<b>Operating result</b>	<b>-224.883</b>	<b>-543.634</b>
Interest and similar income	32.281.559	74.562.414
- Interest and similar expense	-28.982.031	-72.706.472
<b>Result before tax</b>	<b>3.074.645</b>	<b>1.312.308</b>
- Income tax expense	-751.661	-2.592.683
<b>Result after tax</b>	<b>2.322.984</b>	<b>-1.280.375</b>

To the shareholders' meeting we propose to allocate the result as follows:

Profit of the financial year	€2.322.984
Profit to carry forward	€2.322.984

### Business Outlook

In 2021, Evonik Finance B.V. will focus on its activities with regards to the granting of loans to foreign subsidiaries and joint ventures. Whilst uncertain, we do not believe, that the impact of the COVID-19 virus would have a material adverse effect on our financial condition or liquidity.

Evonik has a debt issuance program to place bonds with a total volume of up to €5 billion. By December 31, 2020 four bonds with a total nominal value of €2,50 billion have been issued under this program.

### Bonds issued under the debt issuance program

	Nominal value in € million	Rating (S&P / Moody's)	Maturity	Coupon in percent	Issue price in percent
<b>Evonik Industries AG</b>					
Fixed-interest bond 2015/2023	750	BBB+ / Baa1	Jan. 23, 2023	1,000	99,337
Fixed-interest bond 2020/2025	500	BBB+ / Baa1	Sept.18, 2025	0,625	99,559
<b>Evonik Finance B.V.</b>					
Fixed-interest bond 2016/2024	750	BBB+ / Baa1	Sept. 7, 2024	0,375	99,490
Fixed-interest bond 2016/2028	500	BBB+ / Baa1	Sept. 7, 2028	0,750	98,830

The obligations of Evonik Finance B.V. under the two outstanding bond maturities towards investors are guaranteed by Evonik Industries AG.

## Major Events

In December 2020, we redeemed three months before the regular maturity date by exercising a right of early termination the bond issued in 2016, which had a nominal value of €650 million.

## Research and development

Evonik Finance B.V. had no activity, nor has it made expenses regarding research and development.

## Financial instruments/ Risks and uncertainties

The financial-economic risk management of Evonik Finance B.V. is based on Treasury-Management-systems implemented throughout the Evonik Group, as well as strict guidelines and principles.

## Risk strategy

Evonik's risk management includes a risk detection system, which meets the requirements for publicly listed companies. The aims are to identify risks as early as possible and to define measures to counter and minimize them. To ensure optimal use is made of opportunities, these also need to be recognized and tracked from an early stage. Evonik only enter into entrepreneurial risks if Evonik is convinced that in this way Evonik can generate a sustained rise in the value of the company and, at the same time, permanently limit possible negative implications.

## Structure and organization of risk management

At Group level, risk management is assigned to the chief financial officer and is organized on a decentralized basis in line with Evonik's organizational structure. The chemicals divisions, corporate center, service units, and other organizational units bear prime responsibility for risk management. That comprises early identification of risks and estimating their implications. Furthermore, suitable preventive and control measures have to be introduced and internal communication of risks must be ensured. Risk coordinators in the organizational units are responsible for agreeing on the relevant risk management activities. At all levels in the Group, systematic and timely risk reporting is a key element in strategic and operational planning, the preparation of investment decisions, projections, and other management and decision-making processes.

A central corporate risk officer coordinates and oversees the processes and systems. The corporate risk officer is the contact for all risk coordinators and is responsible for information, documentation, and coordination at Group level. Further responsibilities include ongoing development of the methodology used by the risk management system. The risk committee is chaired by the chief financial officer and composed of representatives of the corporate center. It validates the group-wide risk situation and verifies that it is adequately reflected in financial reporting. The supervisory board, especially the audit committee, oversees the risk management system.

The internal audit function of Evonik monitors risk management and the organizational units to make sure they comply with statutory and internal requirements and to ensure the continuous improvement of risk management. The risk detection system is included in the annual audit in compliance with the requirements for listed companies. This audit showed that Evonik's risk detection system is suitable for timely identification of risks that could pose a threat to the company's survival.

The organizational units conduct an extensive annual risk inventory in connection with the mid-term planning process. They are required to provide details of the measures to be taken with regard to the risks identified, introduce them immediately, and track their timely implementation. Internal management (for example, reporting by the risk committee) takes a mid-term view. The opportunities and risks identified are classified as low, moderate, or high (see opportunity and risk matrix). The evaluation is always based on a net view, in other words, taking into account risk limitation measures. Risk limitation measures can reduce, transfer, or avoid gross risks. Common measures include economic mitigation measures, insurance, and the establishment of provisions on the balance sheet.

On November 11, 2016 an audit committee for Evonik Finance B.V. has been implemented. The audit committee has three members (two externals and one internal) and the members have specialist knowledge and experience in the application of accounting standards, finance and internal control system. The Company complies with the applicable Dutch requirements for the composition of the audit committee.

### **Overall assessment of opportunities and risks**

Given the measures planned and implemented, as of the reporting date no risks have been identified that—either individually or in conjunction with other risks—could jeopardize the continued existence of Evonik as a whole, including Evonik Industries AG in its role as the holding company for the Group. The same applies on the level of Evonik Finance B.V. on a stand-alone basis.

Overall, more risks than opportunities materialized in all segments in 2020. Evonik's reporting distinguishes between the categories markets and competition, legal and compliance, and process and organization. The main parameters influencing the risk categories in terms of both opportunities realized and risks that materialized resulted from the development of specific market and competitive situations. From the present standpoint, the risks for 2021 again outweigh the potential opportunities. Due to the ongoing uncertainty for the Evonik Group as a result of the coronavirus pandemic, both opportunities and risks have increased compared with 2020.

### **Compliance risks**

Compliance means lawful business conduct. The principal compliance rules are set out in the Evonik Code of Conduct, which explicitly prohibits, for example, all forms of corruption, including “facilitation payments,” and violation of antitrust regulations. Risks could result from failure to comply with the corresponding regulations. To minimize compliance risks, extensive training and sensitization of employees is undertaken at face-to-face training sessions and/or through e-learning programs. Evonik's code of conduct is binding for all Evonik employees worldwide, including the executive board and the governance bodies of all Evonik companies. They are required to comply with the rules set forth in the code of conduct, to ensure they are familiar with its content, and to take part in the relevant training.

Evonik monitors the observance of human rights along the value chain. To minimize the related risks, Evonik requires compliance with the code of conduct for suppliers, the global social policy, and the policy statement on human rights.

### **Liquidity risks**

To manage the Group's solvency, Evonik uses central liquidity risk management. At its heart is a group-wide cash pool. In addition, Evonik's financial independence is secured through a broadly diversified financing structure, a €1.75 billion revolving credit facility as a central source of liquidity, and Evonik's

solid investment grade rating. Overall, Evonik believes that adequate financing instruments are available to ensure sufficient liquidity at all times.

### **Legal risks**

Evonik is exposed to legal risks, resulting, for example, from legal disputes such as claims for compensation, and from administrative proceedings and fines. In its operating business, the Evonik Group is exposed to liability risks, especially in connection with product liability, patent law, tax law, competition law, antitrust law, and environmental law.

### **Default risks**

Default risks involve the risk of a loss if our debtors are fully or partially unable to meet their payment commitments. The credit risk of our customers and financial counterparties is therefore systematically examined when the contracts are concluded and monitored continuously afterwards. Limits are set for each contractual partner on the basis of internal or rating-based creditworthiness analyses.

### **Interest rates and exchange rates risks**

In the course of its business, Evonik Finance B.V. is exposed to the risk of changes in exchange rates and interest rates. These risks are mitigated on holding level at Evonik. A detailed overview of interest rate and foreign exchange management and the use of financial derivatives is given in the notes to the financial statements.

### **COVID-19**

As explained in note 4.6 *Covid-19* in the financial statements, the COVID-19 outbreak and resulting measures taken by various governments to contain the virus have had a minimal impact on our business in 2020. In addition to the already known effects, the macroeconomic uncertainty causes disruption to economic activity and it is unknown what the longer-term impact on our business may be. The scale and duration of this pandemic remain uncertain. The main risks and uncertainties for Evonik Finance B.V. that result from the current uncertain situation regarding COVID-19 are:

- Financial assets: We have up to now no reason to believe that the borrowers are not able to repay the loans on the maturity date of the loans.
- Financing: We do not expect any COVID-19 related risk to the financing of Evonik Finance B.V.

Whilst uncertain, we do not believe, that the impact of the COVID-19 virus would have a material adverse effect on our financial condition or liquidity.

**Management statement**

We hereby declare, to the best of our knowledge, the financial statements prepared in accordance with the applicable set of accounting standards give a true and fair view of the assets, liabilities, financial position and profit or loss of the issuer. The management report includes a fair review of the development and performance of the business and the position of Evonik Finance B.V., together with a description of the principal risks and uncertainties that they face.

The executive board comprises one woman and one man. In compliance with statutory requirements, it therefore meets the minimum of 30 percent women and 30 percent men.

Amsterdam, March 24, 2021

Laila Aoulad Si Kaddour  
Director

Alexander van der Weiden  
Director

# FINANCIAL STATEMENTS

## Company financial statements

### 1 Balance sheet as at December 31, 2020 (after appropriation of result)

#### Assets

	Note	31-12-2020 €	31-12-2019 €
<b>Non-current assets</b>			
<b>Financial fixed assets</b>			
Loans to group companies	8.1	998.541.385	1.458.140.984
Deferred tax asset	8.2	58.172	808.540
Derivatives	8.3	-	34.503.801
		<b>998.599.557</b>	<b>1.493.453.325</b>
<b>Current assets</b>			
Loans to group companies	8.4	453.534.584	21.000.000
Receivables from group companies	8.5	519.469	628.544.245
Interest receivable	8.6	5.964.594	6.098.010
Tax receivables	8.7	663.729	11.837
Other receivables	8.8	2.267	2.267
Derivatives	8.3	71.853.747	-
		<b>532.538.390</b>	<b>655.656.359</b>
<b>TOTAL ASSETS</b>		<b>1.531.137.947</b>	<b>2.149.109.684</b>

**Equity and Liabilities**

		31-12-2020	31-12-2019
	Note	€	€
<b>Equity</b>			
	8.9		
Issue share capital		50.000	50.000
Share premium		232.190.000	232.190.000
Revaluation Hedge Reserve		-1.954.663	-2.130.284
Retained earnings		16.694.160	14.371.176
		<b>246.979.497</b>	<b>244.480.892</b>
<b>Non-current liabilities</b>			
Bonds	8.10	1.242.655.516	1.892.444.599
		<b>1.242.655.516</b>	<b>1.892.444.599</b>
<b>Current liabilities</b>			
Creditors	8.11	67.662	18.175
Loans from group companies	8.12	-	10.000.000
Interest payable to group companies	8.13	-	86.100
interest payable on bonds	8.14	2.085.617	2.079.918
Payable to group companies	8.15	38.638.267	-
Taxes payables	8.16	711.388	-
		<b>41.502.934</b>	<b>12.184.193</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>1.531.137.947</b>	<b>2.149.109.684</b>

## 2 Income statement for the year ended December 31, 2020

	Notes	2020 €	2019 €
<b>Income</b>			
Interest and similar income	9.1	32.281.559	74.562.414
<b>Expenses</b>			
Interest and similar expenses	9.1	<u>-28.982.031</u>	<u>-72.706.472</u>
<b>Financial result</b>		<b>3.299.528</b>	<b>1.855.942</b>
<b>General and administrative expenses</b>			
Personnel expenses	9.2	-13.584	-13.452
Other operating expenses	9.2	<u>-211.299</u>	<u>-530.182</u>
<b>Operating result</b>		<b>-224.883</b>	<b>-543.634</b>
<b>Income before tax</b>		<b>3.074.645</b>	<b>1.312.308</b>
Income tax expense	9.4	<u>-751.661</u>	<u>-2.592.683</u>
<b>Profit/Loss after tax</b>		<b><u>2.322.984</u></b>	<b><u>-1.280.375</u></b>

### 3 Cash flow statement for the year ended December 31, 2020

	Notes	2020 €	2019 €
<b>Operating result</b>		<b>-224.883</b>	<b>-543.634</b>
Change in other working capital			
- Accounts payable		38.687.754	-5.711.861
- Receivables		628.024.438	-623.959.474
		666.712.192	-629.671.335
Received interest		32.414.975	52.011.823
Paid interest		-29.058.405	-40.954.201
Taxes paid		-	-607.932
<b>Cash flow generated from operating activities</b>	<b>4.8</b>	<b>669.843.879</b>	<b>-619.765.279</b>
<b>Cash flow generated from investing activities</b>	<b>4.8</b>	<b>-</b>	<b>-</b>
Loans from Evonik Industries	8.3 8.12	-47.349.945	-81.273.799
Loans to other companies	8.1 8.4	27.065.015	705.843.198
Issued Bonds	8.10	-649.789.082	2.358.470
<b>Cash flow generated from financing activities</b>	<b>4.8</b>	<b>-670.074.012</b>	<b>626.927.869</b>
Effect of exchange rate differences		230.133	-7.162.590
Changes in cash and cash equivalents		-	-
Cash and cash equivalents January 1		-	-
<b>Cash and Cash equivalents December 31</b>		<b>-</b>	<b>-</b>

## 4 General information

### 4.1 Operations

Evonik Finance B.V. is a 100% subsidiary of Evonik Industries AG. As such its primary goals are to cover for the structural financing needs from Evonik group companies and joint-ventures, by providing loans and guarantees. Borrowing and bond issuance are normally undertaken by Evonik Industries AG or its financing subsidiary Evonik Finance B.V., whose liabilities are fully guaranteed by Evonik Industries AG. To reduce external borrowing, surplus liquidity at Group companies is placed in a cash pool at Group level to cover financing requirements in other Group companies through intragroup loans. Evonik has a flexible range of corporate financing instruments to meet liquidity requirements for day-to-day business, investments, and the repayment of financial debt.

Evonik has a solid investment grade rating. It still has a rating of Baa1 from Moody's and BBB+ from Standard & Poor's. The outlook for the S&P rating is stable. In April 2020, Moody's reduced its outlook for the Baa1 rating from stable to negative. Maintaining a solid investment grade rating is a central element in Evonik's financing strategy. In this way Evonik gains access to a broad investor base on appropriate financing terms and thus maintain Evonik's financial flexibility. A solid investment grade rating gives banks, investors, customers, and suppliers a reliable basis for a long-term business relationship with Evonik. This combined with the Evonik Industries AG unlimited and unconditional guarantee should be considered the basis for Evonik Finance B.V.'s activities on the international debt capital markets.

### 4.2 Group structure

Evonik Finance B.V. is a member of the Evonik group. The ultimate parent company of this group is Evonik Industries AG located in Essen (Germany). The financial statements of Evonik Finance B.V. are included in the consolidated financial statements of Evonik Industries AG located in Essen (Germany).

### 4.3 Foundation

Evonik Finance B.V. was founded on December 15, 2010 with an authorized share capital of €250.000 (paid in €50.000) and is located at the following address: Hettenheuvelweg 37, 1101 BM Amsterdam, the Netherlands. Evonik Finance B.V registered at the chamber of commerce under number 51480433.

### 4.4 Related-party transactions

All legal entities that can be controlled, jointly controlled or significantly influenced are considered to be a related party. The shareholder of the company is Evonik Industries AG located in Essen (Germany). All companies in which Evonik Industries AG ultimately has a majority interest are considered to be a related party.

Significant transactions with related parties are disclosed in the notes insofar as they are not transacted under normal market conditions. The nature, extent and other information is disclosed if this is required for to provide the true and fair view.

### 4.5 Going Concern

The company generated a profit of €2.322.984 for the period from January 1 to December 31, 2020, which, resulted in equity of €246.979.497 (December 31, 2019: €244.480.892). The earnings of the company will be determined by income items associated with the on-lending of raised funds, and profitability will be

based on the margins obtained from the on-lending in excess of the interest to be paid on the notes and the service charges. Based on that, Evonik Finance B.V. will achieve a reasonable profit under these circumstances. Finally, Evonik Finance B.V. is supported by the unconditional and unlimited guarantee of Evonik Industries AG and is furthermore participating in the cashpool lead by Evonik. The accounts have therefore been prepared based upon the going concern principle.

#### 4.6 *COVID-19*

The Covid-19 outbreak and the resulting measures taken by various governments to contain the virus have impacted the business of Evonik. Evonik has identified the risks, has taken measures to monitor and prevent the effects of the COVID-19 virus such safety and health measures for our people (like social distancing and working from home). At this time, the impact on our business and results has been small. We will continue to follow the various national institutes policies and advice. In parallel we will do our utmost to continue our operations in the best and safest way possible. The main risks and uncertainties for Evonik Finance B.V. that result from the current uncertain situation regarding COVID-19 are:

- Financial assets: We have up to now no reason to believe that the borrowers are not able to repay the loans on the maturity date of the loans.
- Financing: We do not expect any COVID-19 related risk to the financing of Evonik Finance B.V.

Whilst uncertain, we do not believe, that the impact of the COVID-19 virus would have a material adverse effect on our financial condition or liquidity.

#### 4.7 *Estimates*

In applying the principles and policies for preparing the financial statements, the directors of Evonik Finance B.V. make different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the true and fair view required under Book 2, article 362, paragraph 1 of the Dutch Civil code, the nature of these estimates and judgments, including assumptions related to the uncertainties, is disclosed in the notes to the relevant financial statement items. Refer to note 8.1 and 8.10 of the financial statement.

#### 4.8 *Notes to the cash flow statement 2020*

The cash flow statement is calculated using the indirect method. The cash items disclosed in the cash flow statement are comprised of cash and cash equivalents. Cash flows denominated in foreign currencies have been translated at average estimated exchange rates. Exchange differences affecting cash items are shown separately in the cash flow statement. Interest paid and received, and income taxes are included in cash from operating activities. Issued loans and received loans to and from group companies, changes in bond values and proceeds from capital increases are included in cash from financing activities. Transactions not resulting in inflow or outflow of cash, are not recognized in the cash flow statement.

## 5 Accounting policies for the balance sheet

### 5.1 General information

The consolidated financial statements have been prepared in accordance with the statutory provisions of Part 9, Book 2, of the Netherlands Civil Code and the firm pronouncements in the Dutch Accounting Standards for Annual Reporting in the Netherlands as issued by the Dutch Accounting Standards Board. The financial statements are denominated in Euro(s).

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. If not specifically stated otherwise, they are recognized at the amounts at which they were acquired or incurred. The balance sheet and income statement include references to the notes.

### 5.2 Prior-year comparison

The valuation principles and method of determining the result are the same as those used in the previous year. The accounting policies have been consistently applied to all the years presented.

### 5.3 Foreign currencies

The financial statements are presented in Euro(s), which is the functional and presentation currency of Evonik Finance B.V.

Foreign currency transactions in the reporting period are translated into the functional currency using the exchange rates prevailing at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the rate of exchange prevailing at the balance sheet date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates are recognized in the income statement.

Translation differences on non-monetary assets held at cost are recognized using the exchange rates prevailing at the dates of the transactions (or the approximated rates).

### 5.4 Financial fixed assets

Receivables disclosed under financial fixed assets are recognized initially at fair value of the amount owed net of any provisions considered necessary. These receivables are subsequently measured at amortized cost. Interests are accrued until date of payment.

### 5.5 Deferred tax asset

Deferred tax assets are recognized for all deductible temporary differences between the value of the assets and liabilities under tax regulations on the one hand and the accounting policies used in these financial statements on the other, on the understanding that deferred tax assets are only recognized insofar as it is probable that future taxable profits will be available to offset the temporary differences and available tax losses. The calculation of the deferred tax assets is based on the tax rates prevailing at the end of the reporting year or the rates applicable in future years, to the extent that they have already been enacted by law. Deferred income taxes are recognized at nominal value.

## 5.6 *Loans to group companies*

Loans to group companies under current assets are recognized initially at fair value of the amount owed net of any provisions considered necessary. These receivables are subsequently measured at amortized cost. Interests are accrued until date of payment.

## 5.7 *Receivables*

Receivables are recognized initially at fair value and subsequently measured at amortized cost. If payment of the receivable is postponed under an extended payment deadline, fair value is measured on the basis of the discounted value of the expected revenues. Interest gains are recognized using the effective interest method. When a receivable is uncollectible, it is written off against the allowance account for receivables.

## 5.8 *Other receivables*

Other receivables presented under current assets include trade receivables. Trade receivables are recognized initially at fair value and subsequently measured at amortized cost.

## 5.9 *Derivatives*

Derivatives are initially recognized in the balance sheet at fair value, the subsequent valuation of derivative financial instruments depends on whether or not the instrument is quoted on an open market. If the underlying object of the derivative financial instrument is listed on a stock exchange, it is valued at fair value. If the object is not listed, it will be stated at cost of current value, if lower. Recognition of changes in the value of a derivative financial instrument is dependent on whether or not the instrument is designated as a hedging instrument to which hedge accounting is applied. These derivative financial instruments are stated at fair value. The method for of accounting for changes in the value of the derivative instruments depends on whether hedge accounting is applied.

Fair value is the amount for which an asset could be exchanged, or a liability settled, between knowledgeable, willing parties in an arm's length transaction. If no fair value can be readily and reliably established, fair value is approximated by deriving it from the fair value of components or of a comparable financial instrument, or by approximating fair value using valuation models and valuation techniques. Valuation techniques include using recent arm's length market transactions between knowledgeable, willing parties, if available; reference to the current fair value of another instrument that is substantially the same; discounted cash flow analysis and option pricing models, making allowance for entity-specific inputs.

Evonik Finance B.V. applies hedge accounting. In close cooperation with Evonik Industries AG, Evonik Finance B.V. documents the relationship between hedging instruments and hedged items at the inception of the transaction and also tests its assessment, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in fair values or cash flows of hedged items. This can be done by comparing the critical characteristics of the hedge instrument with those of the hedged position, and/or by comparing the change in the fair value of the hedge instrument with the hedged position. If there is an indication of ineffectiveness, the company measures this potentially ineffective part by conducting a quantitative ineffectiveness measurement. There are no ineffective parts, there is an approximating critical term match. Critical features include the notional amount, the term, the hedged risk and the method of settling the hedge instrument and the hedged item. Notional and maturity of the derivative and the loans match perfectly.

To measure the fair value of the cross-currency interest rate swap, future cash flows are calculated and then discounted. The calculated cash flows result from the contract conditions and the USD forward exchange rate (development of exchange rates expected by the market). Discounting is based on market interest rate data as of the reporting date for comparable instruments (EURIBOR rate of the same tenor).

With a cash flow hedge, the changes in fair value of the derivative hedging instrument are recognized in the cash flow hedge reserve to the extent that the hedge is effective. Amounts accumulated in the cash flow hedge reserve are reclassified to the income statement at the same time that the underlying hedged item affects net income. To the extent that the hedge is ineffective, the change in fair value is immediately recognized in net interest in the income statement.

The purpose of fair value hedges is to hedge the fair value of assets or liabilities reflected on the balance sheet. Both changes in the fair value of the hedging instrument and changes in the value of the hedged item is recognized in the income statement. In view of this method, changes in the value of the hedged item and the hedge cancel each other out in the income statement.

Evonik Finance B.V. shall discontinue hedge accounting if:

- The hedging instrument expires or is sold, terminated or exercised
- The hedge no longer meets the criteria for hedge accounting
- The company revokes the designation

Evonik Finance B.V. assesses at each balance sheet date whether there is objective evidence that a financial asset or a group of financial assets is impaired. If any such evidence exists, the impairment loss is determined and recognized in the income statement.

The amount of an impairment loss incurred on financial assets stated at amortized cost is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss shall be reversed. The reversal shall not result in a carrying amount of the financial asset that exceeds what the amortized cost would have been had the impairment not been recognized at the date the impairment is reversed. The amount of the reversal shall be recognized through profit or loss.

#### **5.10 Revaluation reserve**

Changes in the value of assets that are measured at fair value are included in the revaluation reserve. Realized fair value changes related to loans and financial instruments as included in current assets are released to the income statement from the revaluation reserve upon realization.

#### **5.11 Deferred tax liability**

Deferred tax liabilities are recognized for temporary differences between the value of the assets and liabilities under tax regulations on the one hand and the book values applied in these financial statements on the other. The computation of the deferred tax liabilities is based on the tax rates prevailing at the end of the reporting year or the rates applicable in future years, to the extent that they have already been enacted by law. Deferred tax balances are valued at nominal value.

### 5.12 *Non-current Liabilities*

Long-term borrowings are initially recognized at fair value, net of transaction costs incurred. Long-term borrowings are subsequently stated at amortized costs, being the amount received taking account of any premium or discount, less transaction costs.

Any difference between the proceeds (net of transaction costs) and the redemption value is recognized as interest in the income statement over the period of the long-term borrowings using the effective interest method.

Evonik Finance B.V. assesses at each balance sheet date whether there is objective evidence that a financial liability or a group of financial liabilities is impaired. If any such evidence exists, the impairment loss is determined and recognized in the income statement.

The amount of an impairment loss incurred on financial liabilities stated at amortized cost is measured as the difference between the liabilities' carrying amount and the present value of estimated future cash flows, discounted at the financial liabilities' original effective interest rate (i.e. the effective interest rate computed at initial recognition). If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss shall be reversed. The reversal shall not result in a carrying amount of the financial liability that exceeds what the amortized cost would have been had the impairment not been recognized at the date the impairment is reversed. The amount of the reversal shall be recognized through profit or loss.

### 5.13 *Current liabilities*

Short-term borrowings are initially recognized at fair value, net of transaction costs incurred. After initial recognition short-term borrowings are subsequently stated at amortized costs, being the amount received taking account of any premium or discount, less transaction costs.

Any difference between the proceeds (net of transaction costs) and the redemption value is recognized as interest in the income statement over the period of the long-term borrowings using the effective interest method.

### 5.14 *Contingent liabilities*

Contingent liabilities are possible or present financial obligations arising from past events where an outflow of resources is not probable, but which are not recognized on the balance sheet.

## 6 Accounting policies for the income statement

### 6.1 General determination of result

The result is the difference between the financial income, financial expenses and the costs and other charges during the year. The results on transactions are recognized in the year in which they are realized.

### 6.2 Financial income and expenses

Interest paid and received is recognized on a time-weighted basis, taking account of the effective interest rate of the assets and liabilities concerned. When recognizing interest paid, allowance is made for transaction costs on loans received as part of the calculation of effective interest.

Changes in the value of financial instruments recognized at fair value are recorded in the profit and loss account.

### 6.3 General and administrative expenses

General and administrative expenses comprise costs chargeable to the year that are not directly attributable to the cost of the goods sold. Costs are allocated to the year to which they relate.

### 6.4 Employee benefits

Employee costs (wages, salaries, social security contributions, etc.) are presented as a separate item in the income statement. Salaries, wages and social security contributions are included in the general and administrative expenses based on the terms of employment, where they are due to employees. Reference is made to note 9.2.

### 6.5 Exchange differences

Exchange differences arising upon the settlement or conversion of monetary items are recognized in the income statement in the period that they arise.

### 6.6 Income tax

Tax on the result is calculated based on the result before tax in the income statement, taking account of the losses available for set-off from previous financial years (to the extent that they have not already been included in the deferred tax assets) and exempt profit components and after the addition of non-deductible costs.

The gross interest income on loans issued to Chinese and Mexican group companies is subject to withholding taxes. Evonik Finance B.V. only receives the net interest, the deducted withholding taxes are directly paid to the tax authorities in China and Mexico. The financial burden of the withholding taxes lies at Evonik Finance B.V.

Withholding taxes that are due on interest received are booked as income tax expense.

## 7 Financial instruments and risk management

All financial risk management of Evonik Finance B.V. is handled centrally by Evonik Industries AG. As an international company, Evonik is exposed to financial risks in the normal course of business. A major objective of corporate policy is to minimize the impact of market, liquidity, and default risks on both the value of the company and profitability in order to check adverse fluctuations in cash flows and earnings without forgoing the opportunity to benefit from positive market trends. For this purpose, a systematic financial and risk management system has been established. Interest rate and exchange rate risks are managed centrally by the Finance division of Evonik Industries AG.

The financial derivatives contracts used by Evonik are entered into exclusively in connection with a corresponding underlying transaction (hedged item) relating to normal operating business, which provides a risk profile directly opposite to that of the hedge. The instruments used are customary products found on the market. For the management of interest rates and exchange rates, they comprise currency swaps, forward exchange contracts, currency options, cross-currency interest rate swaps, and interest rate swaps.

For financial risk management purposes, Evonik applies the principle of separation of front office, risk controlling, and back office functions and takes as its guide the banking-specific minimum requirements for risk management (MaRisk) and the requirements of the German legislation on corporate control and transparency (KonTraG). All material financial risk positions are identified and evaluated in accordance with group-wide policies and principles. This forms the basis for selective hedging to limit risks.

### **Default risk**

The default risk (= credit risk) is managed at group level. Three categories are defined for credit risk management, each of which is treated separately on the basis of its specific features. The categories are financial counterparties (generally banks but also other financial institutions and industrial counterparties, insofar as derivatives transactions are concluded with them), other counterparties (mainly debtors and creditors), and countries. Credit risks are defined generally as a potential threat to earnings power and/or corporate value resulting from a deterioration of the respective contractual counterparty. More precisely, it means defaulting on payments as a result of financial difficulties/insolvency by the counterparty. On principle, Evonik does not hold any purchased or originated credit-impaired financial assets. To monitor any risk concentrations, the individual risk limits are set for business partners on the basis of internal and external ratings.

Credit risks relating to financial contracts are systematically examined when the contracts are concluded and monitored continuously afterwards by Evonik Industries AG.

### **Interest rates and cash flow risk**

The aim of interest rate management is to protect net income from the negative effects of fluctuations in market interest rates and the resulting changes in fair values or cash flows. Interest rate risk is generally managed using derivative and non-derivative financial instruments. The aim is to achieve an appropriate ratio of fixed rates (with interest rates fixed for more than one year) and variable rates (terms of less than one year), taking costs and risks into account.

## ***Currency risk***

Main objective of currency risk management for Evonik Finance B.V. is to eliminate the currency risk relating to financing transactions that are not denominated in the functional currency of the company. Hedge accounting is applied for non-current loans. The hedging instrument and related hedged item are then designated in a formal hedge relationship (cash flow hedge accounting). In the case of hedges on loans, it allows the distribution of hedging costs on a straight-line basis over the term of hedging relationship.

Currency risk management is carried out separately for operational risk positions (mainly trade accounts receivable and payable in foreign currencies) and risk positions arising from current financing activities such as cash pooling, bank deposits, and cash and cash equivalents.

Gross income and expenses from the currency translation of financing-related risk positions and financing-related currency hedging are netted. The resulting net results for currency translation and currency hedging are recognized in other financial income/expense. The net presentation of the results reflects both the management of risk positions in the Evonik Group and the economic substance.

Due to the application of hedge accounting for hedging of foreign currency balance sheet exposure (for example, financing-related currency hedging of non-current loans through cross-currency interest rate swaps) and the hedging of planned or firmly agreed foreign currency cash flows (for example, hedging of forecast sales revenues), the hedge results are only reflected in profit or loss in any ineffective portions that are excluded from the hedge accounting relationship. By contrast, the effective results of hedges reflected in cash flow hedge accounting and the cost of hedging (forward components, time value of options, and foreign currency basis spreads) are recognized in other equity components until the hedged transaction is realized. In the case of currency hedges for loans for which cash flow hedge accounting is applied, the effective portion of the hedge is transferred from other equity components to offset the net result of currency translation of monetary assets and liabilities triggered by the hedged item.

## ***Liquidity risks***

Liquidity risk is managed through business planning to ensure that the funds required to finance the current operating business and current and future investments at all companies in the Evonik Group are available at the right time and in the right currency at optimum cost. Liquidity requirements for business operations, investments, and other financial activities are derived from a financing status and liquidity planning, which form part of liquidity risk management. Liquidity is pooled in a central cash management pool where this makes economic sense and is legally permissible. Central liquidity risk management facilitates low-cost borrowing and advantageous offsetting of financial requirements.

## 8 Notes to the balance sheet as at December 31, 2020

### NON-CURRENT ASSETS

#### 8.1 Loans to group companies

	31/12/2020	31/12/2019
	€	€
Loans to Evonik Operations GmbH	998.541.385	998.286.970
Loan to Evonik Corporation	-	459.854.014
	<b>998.541.385</b>	<b>1.458.140.984</b>

The loans to group companies consist at December 31, 2020 of two Credit Facility Agreements with Evonik Operations GmbH for the facility amount of 1.000.000.000 EUR in total. The Final maturity date is 7 September 2024 for 500.000.000 EUR and 7 September 2028 for another 500.000.000 EUR. Interest has and will be paid at 7 September each year. The average interest rate in 2020 was 1,15%. On 31 December 2020 the loans amounted to €998.541.385, including the disagio.

The below movement schedule shows the changes in the loans during 2020:

	Loans to group 2020	Loans to group 2019
	€	€
<b>Balance as at 1 January</b>	<b>1.458.140.984</b>	<b>1.531.753.113</b>
Repaid loan - Evonik Specialty Chemicals (Shanghai) Co., Ltd	-	-19.047.377,68
Repaid loan - Evonik (China) Co., Ltd	-	-63.491.257
Disagio loan - Evonik Operations GmbH	254.415	251.531
Currency translation effect	-	8.674.975
Reclassification to short term loan	- 459.854.014	-
<b>Balance as at 31 December</b>	<b>998.541.385</b>	<b>1.458.140.984</b>

The total fair value of the loans to group companies approximates € 1.040.000.000 on 31 December 2020.

Evonik Finance B.V. has not and has not been asked to grant any payment holidays on their loans to group companies.

#### 8.2 Deferred tax asset

On December 31, 2020 the deferred tax asset was adjusted. The deferred tax asset on rating agency fees was reduced to €58.172. The deferred tax asset was reduced to €651.554. The deferred tax asset on the revaluation hedge reserve is now short-term, since both the cash flow hedge and the loan granted to Evonik Corporation Ltd have a maturity date in 2021.

The deferred tax asset can be specified as follows:

	Rating agency fees	Revaluation Hedge Reserve	Total
	€	€	€
Balance as at 1 January 2020	98.445	710.095	808.540
Change in deferred tax asset	-40.273	- 710.095	-750.368
<b>Balance as at 31 January 2020</b>	<b>58.172</b>	<b>-</b>	<b>58.172</b>

### 8.3 Derivatives

On 31 December 2020 Evonik Finance B.V. had 1 cashflow hedge (2019: 1 cashflow hedges and 1 fair value hedge).

#### Cross-currency interest rate swap

The notional amounts and fair value of cross-currency interest rate swap is shown in the analysis below.

##### Current assets

Derivative	Start date	Maturity date	Notional value	Dirty market value 31.12.2020	Dirty market value 31.12.2019
Cross-currency swap	03.01.2017	06.05.2021	USD 516.600.000	EUR 71.853.747	EUR 32.556.342

For the cross-currency swap mentioned in the table above hedge accounting is applied. The cross-currency swap is designated in a cash flow hedge.

The cross-currency swap is contracted with Evonik Industries AG to hedge the foreign currency risk on the intercompany loans which are not covered by back to back financing.

The notional amounts correspond to the volume of exposure hedged with the cash flow hedge. The dirty market value consists of the clean market value and the net interest on the derivative. The total change in the clean market value of the cross-currency swaps amounts to €39.095.592. Both the changes in the clean market values of the cross-currency swaps and the revaluation of the loan underlying the financial instrument are recorded in the revaluation hedge reserve. The change in clean market value is shown in the table below.

##### Assets

Derivatives	Start date	Maturity date	Notional value	Clean market value 31.12.2020	Clean market value 31.12.2019	Change in clean market value
Cross-currency swap	03.01.2017	06.05.2021	USD 516.600.000	EUR 71.940.767	EUR 32.845.175	EUR 39.095.592
<b>Total</b>				<b>EUR 71.940.767</b>	<b>EUR 32.845.175</b>	<b>EUR 39.095.592</b>

<b>Total assets and liabilities</b>	<b>EUR 71.940.767</b>	<b>EUR 32.845.175</b>	<b>EUR 39.095.592</b>
-------------------------------------	-----------------------	-----------------------	-----------------------

## CURRENT ASSETS

All receivables mentioned below fall due in less than one year. Due to the short-term nature the fair value approximates the carrying value.

### 8.4 Loans to group companies

	31/12/2020	31/12/2019
	€	€
Loan to Neolyse Ibbenbüren GmbH	18.375.000	21.000.000
Loan to Evonik Corporation	420.992.584	-
Loan to Veramaris V.O.F.	14.167.000	-
	<b>453.534.584</b>	<b>21.000.000</b>

All receivables mentioned above fall due in less than one year.

The short-term loans consist at December 31, 2020 of the following loans:

1. A Credit Facility Agreement with Neolyse Ibbenbüren GmbH for the facility amount of initially 26.250.000 EUR. The availability period started on 10 November 2015. The final maturity date is 31 December 2027. Interest is paid in various periods. The average interest rate in 2020 was 1,15%. On 31 October 2020 Neolyse Ibbenbüren GmbH repaid €2.625.000 of the loan. On 31 December 2020 €18.375.000 has been drawn in several loan tranches.
2. A Credit Facility Agreement with Evonik Corporation for the facility amount of 516.600.000 USD. The availability period started on 20 December 2016 and the loan has been fully drawn on 3 January 2017. The final maturity date for the loan is on 6 May 2021. Interests for this loan will be paid finally on 6 May 2021. The interest rate in 2020 was 3,20%. This loan is fully covered by a cross-currency interest rate swap. On 31 December 2020 the EUR equivalent of this loan amounts to €420.992.584.
3. A Credit Facility Agreement with Veramaris V.O.F. for the facility amount of 14.167.000 EUR. The availability period started on 1 March 2018. The final maturity date is 31 December 2023. Interest is paid in various periods. The average interest rate in 2020 was 0,8%. On 31 December 2020 the facility was fully drawn.

The below movement schedule shows the changes in the loans to group companies during 2020:

	2020	2019
	€	€
<b>Balance as at 1 January</b>	<b>21.000.000</b>	<b>652.961.219</b>
New granted loans - Veramaris V.O.F.	14.167.000	-
Repaid loan - Evonik Corporation	-	-451.179.039
Repaid loan - Neolyse Ibbenbüren GmbH	-2.625.000	-2.625.000
Repaid loan - Evonik Specialty Chemicals (Shanghai) Co.	-	-137.903.012
Repaid loan - Cyplus Idesa S.A.P.I. de C.V.	-	-40.254.168
Currency translation effect	-38.861.430	-
Reclassification to short term loan	459.854.014	-
<b>Balance as at 31 December</b>	<b>453.534.584</b>	<b>21.000.000</b>

### 8.5 Receivables from group companies

	31/12/2020	31/12/2019
	€	€
Cashpool	1.116	628.025.892
Other receivables from group companies	518.353	518.353
	<u>519.469</u>	<u>628.544.245</u>

The cashpool reflects a position towards Evonik Industries AG. The average interest rate on the cashpool is 0% (2019: 0%).

The company holds accounts with the Unicredit, HSBC bank and the JP Morgan bank. These accounts have a zero balance (due to the cash pooling with Evonik Industries AG) at the balance sheet date.

The other receivable from group companies relates to a receivable position towards Evonik Industries AG as a result of the termination of the loans to Cyplus Idesa S.A.P.I. de C.V.

### 8.6 Interest receivable

	31/12/2020	31/12/2019
	€	€
Accrued Interest Neolyse Ibbenbüren GmbH	155.066	160.521
Accrued interest Evonik Operations GmbH	3.648.438	3.648.438
Accrued interest Evonik Corporation	2.095.608	2.289.051
Accrued interest Veramaris V.O.F.	65.482	-
	<u>5.964.594</u>	<u>6.098.010</u>

All receivables mentioned above fall due in less than one year.

### 8.7 Tax receivables

	12/31/2020	12/31/2019
	€	€
Tax receivables	12.175	11.837
Deferred tax asset	651.554	-
	<u>663.729</u>	<u>11.837</u>

All receivables mentioned above fall due in less than one year.

### 8.8 Other receivables

	31/12/2020	31/12/2019
	€	€
Prepaid expenses	2.267	2.267
	<u>2.267</u>	<u>2.267</u>

All receivables mentioned above fall due in less than one year.

## EQUITY AND LIABILITIES

## 8.9 Equity

	Issued share capital	Share premium	Revaluation Hedge Reserve	Retained earnings	Total
	€	€	€	€	€
At January 1, 2019	50.000	232.190.000	830.008	15.651.551	248.721.559
Changes					
Revaluation Hedge Reserve	-	-	-3.947.056	-	-3.947.056
Deferred taxes on OCI	-	-	986.764	-	986.764
Result at December 31, 2019	-	-	-	-1.280.375	-1.280.375
At December 31, 2019	50.000	232.190.000	-2.130.284	14.371.176	244.480.892

	Issued share capital	Share premium	Revaluation Hedge Reserve	Retained earnings	Total
	€	€	€	€	€
At January 1, 2020	50.000	232.190.000	-2.130.284	14.371.176	244.480.892
Changes					
Revaluation Hedge Reserve	-	-	-475.933	-	-475.933
Deferred taxes on OCI	-	-	651.554	-	651.554
Result at December 31, 2020	-	-	-	2.322.984	2.322.984
At December 31, 2020	50.000	232.190.000	-1.954.663	16.694.160	246.979.497

**Share capital**

At the balance sheet date, the authorized share capital of Evonik Finance B.V. amounts to €250.000, divided into 2.500 ordinary shares of € 100 each. Of these, 500 ordinary shares have been issued and fully paid. All shares are held by Evonik Industries AG.

**Revaluation hedge reserve**

The revaluation hedge reserve can be considered as a legal reserve and can therefore not be distributed as dividend to the shareholder.

Hedge accounting was applied on the outstanding financial instruments (cash flow hedge) between Evonik Industries AG and Evonik Finance B.V.

The balance in the revaluation hedge reserve can be broken down as follows:

Revaluation Hedge Reserve	Clean market value change	Currency translation effects loans	Total	Deferred taxes	Total
At January 1, 2020	€ 32.845.175	€ -35.685.554	€ -2.840.379	€ 710.095	€ -2.130.284
Changes	€ 39.095.592	€ -38.861.430	€ 234.162	€ -58.541	€ 175.621
At December 31, 2020	€ 71.940.767	€ -74.546.984	€ -2.606.217	€ 651.554	€ -1.954.663

Additionally, a deferred tax asset of €651.554 was created for the amount in the revaluation hedge reserve.

**Proposed appropriation of result**

Following the profit appropriation proposed by the Management Board and pursuant to Article 18 sub 2 of the Articles of Association, the Management Board proposes to add the profit of €2.322.984 to the retained earnings reserves.

The management proposes the following appropriation of result:

	<u>2020</u>
	€
Addition to retained earnings reserve	2.322.984
	<hr/>
Total addition to the retained earnings	2.322.984

This proposal, that is yet to be approved by the general meeting of shareholders, has already been taken into account in this annual statutory account.

## NON-CURRENT LIABILITIES

### 8.10 Bonds

On September 7, 2016 Evonik Finance B.V. issued bonds with a nominal value of €1,9 billion. In total Evonik Finance B.V. issued three fixed tranches:

1. €650 million with a tenor of 4.5 years and a coupon of 0%. Issued price: 99,771%
2. €750 million with a tenor of 8 years and a coupon of 0,375%. Issued price: 99,490%
3. €500 million with a tenor of 12 years and a coupon of 0,750%. Issued price 98,830%

The bonds were issued at discount. The obligations of Evonik Finance B.V. under the bonds towards investors are guaranteed by Evonik Industries AG.

On December 8, 2020 Evonik Finance B.V. repaid the €650 million bond. For this bond a fair value hedge was closed and contracted with Evonik Industries AG. The fair value hedge also matured on December 8, 2020.

	Nominal value in € million	Rating (S&P/Moody)	Issue price in percent	Fair value price in € 31.12.2020	Maturity	Coupon in percent	Interest payment date	Interest in €	Book value in € 31.12.2020	Duration
Fixed interest bond 2016/2024	750.000.000	BBB+/Baa1	99,490	754.500.000	07.09.2024	0,375	07.09.2020	893.836	747.381.660	≥1 years- 5 years
Fixed interest bond 2016/2028	500.000.000	BBB+/Baa1	98,830	519.900.000	07.09.2028	0,750	07.09.2020	1.191.781	495.273.856	> 5 years
<b>Total</b>	<b>1.250.000.000</b>			<b>1.274.400.000</b>				<b>2.085.617</b>	<b>1.242.655.516</b>	

The total fair value of the bonds approximates €1.274.400.000 on December 31, 2020.

The movement schedule for the bonds is as follows:

	<b>2020</b>	<b>2019</b>
	€	€
Balance as at 1 January	1.892.444.599	1.890.086.128
Disagio	2.046.459	1.909.561
Termination of fair value hedge	-1.835.542	-
Fair value Hedge	-	448.910
Repayment bond	-650.000.000	-
Balance as at 31 December	<hr/> 1.242.655.516	<hr/> 1.892.444.599

**CURRENT LIABILITIES**

All liabilities mentioned below fall due in less than one year. Due to the short-term nature the fair value approximates the carrying value.

**8.11 Creditors**

	31/12/2020	31/12/2019
	€	€
Creditors - group companies	43.478	-
Creditors - external	24.184	18.175
	<u>67.662</u>	<u>18.175</u>

The creditors mentioned above fall due in less than one year.

**8.12 Loans from group companies**

	31/12/2020	31/12/2019
	€	€
Loan from Evonik Industries AG (“Neolyse”)	-	10.000.000
	<u>-</u>	<u>10.000.000</u>

The movement schedule for the loans from group companies is as follows:

	2020	2019
	€	€
<b>Balance as at 1 January</b>	<b>10.000.000</b>	<b>143.540.686</b>
Repayment loan - Evonik Industries AG (“Neolyse”)	-10.000.000	-13.625.000
Repaid loan -Evonik Industries AG (“Shanghai”)	-	-89.522.673
Repaid loan -Evonik Industries AG (“Cyplus”)	-	-30.393.013
<b>Balance as at 31 December</b>	<u><b>-</b></u>	<u><b>10.000.000</b></u>

**8.13 Interest payable to group companies**

	31/12/2020	31/12/2019
	€	€
Interest Loan Evonik Industries AG („Neolyse“)	-	86.100
	<u>-</u>	<u>86.100</u>

**8.14 Interest payable on bonds**

	31/12/2020	31/12/2019
	€	€
Interest on bonds	2.085.617	2.079.918
	<u>2.085.617</u>	<u>2.079.918</u>

The interest on bonds can be broken down as follows:

	Nominal value in € million	Rating (S&P/Moo dy)	Issue price in percent	Maturity	Coupon in percent	interest payment date	Interest in €
Fixed interest bond 2016/2024	750.000.000	BBB+/Baa1	99,490	07.09.2024	0,375	07.09.2020	893.836
Fixed interest bond 2016/2028	500.000.000	BBB+/Baa1	98,830	07.09.2028	0,750	07.09.2020	1.191.781
<b>Total</b>	<b>1.250.000.000</b>						<b>2.085.617</b>

#### 8.15 Payable to group companies

	31/12/2020	31/12/2019
	€	€
Cashpool	38.638.267	-
	<b>38.638.267</b>	<b>-</b>

The cashpool reflects a position towards Evonik Industries AG. The average interest rate on the cashpool is 0% (2019: 0%).

#### 8.16 Taxes payable

	31/12/2020	31/12/2019
	€	€
Corporate income tax	711.388	-
	<b>711.388</b>	<b>-</b>

#### 8.17 Contingent liabilities

As per 31 December 2020 there are two outstanding guarantee that should be considered as a contingent liability totaling € 2,7 million (2019: €2,9 million). A guarantee of €1,2 million was granted to the German European School Singapore (GESS) to secure the facility agreement between GESS and Deutsche Bank AG. A guarantee of €1,5 million was granted for the benefit of Raiffeisenbank Leoben-Bruck eGen securing 49% of the debt obligations of LiteCon GmbH under certain loan agreements.

## 9 Notes to the income statement for the year ended December 31, 2020

### 9.1 Financial income and expense

<b>Financial income</b>	<b>2020</b>	<b>2019</b>
	€	€
Interest loan Cyplus Idesa S.A.P.I. de C.V.	-	1.743.562
Interest loan Evonik Specialty Chemicals (Shanghai)	-	3.223.226
Interest loan Evonik (China) Co., Ltd.	-	2.128.083
Interest loan Evonik Operations GmbH	11.734.415	11.731.531,00
Interest loan Neolyse Ibbenburen GmbH	240.134	270.262
Interest loan Evonik Corporation	14.658.095	19.168.273
Interest loan Veramaris V.O.F.	65.482	-
Interest financial derivatives	5.583.413	4.972.374
Interest on cash pool	20	994
Gain valuation derivatives	-	31.054.258
Reversal depreciation loan Cyplus Idesa S.A.P.I. de C.V.	-	269.851
	<b>32.281.559</b>	<b>74.562.414</b>
<b>Financial expenses</b>	<b>2020</b>	<b>2019</b>
	€	€
Interest loan Cyplus Idesa S.A.P.I. de C.V.	-	413.051
Interest loan Evonik Industries AG ("Shanghai")	-	1.525.962
Interest loan Evonik Industries AG („Neolyse“)	5.250	171.984
Interest bonds	8.614.658	8.466.363
Interest financial derivatives	14.658.095	22.158.351
Interest cash pool	-	969
Guarantee fees	5.700.000	5.700.000
Bank charges	3.914	4.450
Exchange rate loss	114	34.265.342
	<b>28.982.031</b>	<b>72.706.472</b>

## 9.2 General and administrative expenses

General and administrative expenses	2020	2019
	€	€
Office expenses	19.100	18.540
Financial services	74.000	71.750
Financial audit fees	36.000	29.000
Management fees	39.400	38.435
Management assistant fees	8.200	7.995
Consultancy and legal fees	-	2.933
Other services	32.787	29.595
Other taxes	-	327.794
IT and Communication expenses	135	520
Travel expenses	1.677	3.620
Wages and salaries	13.584	13.452
	<b>224.883</b>	<b>543.634</b>

The other services can be broken down as follows:

Other services	2020	2019
	€	€
Fee Luxembourg stock exchange	850	500
Fee Commission de Surveillance du sector Financier (CSSF)	6.000	6.000
Fee EQS	3.400	3.116
Fee HR services	3.912	3.729
Yearly remuneration for the Audit Committee members	16.000	16.000
Fee tax related services	2.625	-
Postal charges	-	200
Fee eHerkenning	-	50
	<b>32.787</b>	<b>29.595</b>

There are no other incentives for the Audit Committee members.

## 9.3 Audit fees

The following audit fees were expensed in the income statement in the reporting period:

2020	PricewaterhouseCoopers Accountants N.V.	Total
	€	€
Audit of the financial statements	30.000	30.000
Other audit services	6.000	6.000
Tax services	0	0
Other non-audit services	0	0
	<b>36.000</b>	<b>36.000</b>
2019	PricewaterhouseCoopers Accountants N.V.	Total
	€	€
Audit of the financial statements	29.000	29.000
Other audit services	0	0
Tax services	0	0
Other non-audit services	0	0
	<b>29.000</b>	<b>29.000</b>

The fees listed above relate to the procedures applied to Evonik Finance B.V. only by accounting firms and external independent auditor as referred to in Section 1, subsection 1 of the Audit Firms Supervision Act ('Wet toezicht accountantsorganisaties - Wta') as well as by Dutch and foreign-based accounting firms, including their tax services and advisory groups. These fees relate to the audit of the 2020 financial statements, regardless of whether the work was performed during the financial year.

#### 9.4 *Income tax expense*

The income tax result of €751.661 can be broken down as follows:

	2020	2019
	€	€
Corporate income tax	-711.388	-
Expense deferred taxes	-40.273	-1.984.751
Withholding taxes	-	-607.932
Income tax	<u>-751.661</u>	<u>-2.592.683</u>

<b>Tax calculation</b>	<b>2020</b>	<b>2019</b>
	€	€
Profit before taxes	3.074.645	1.312.308
Theoretical taxes to be paid*	-751.661	-316.077
Corporate income tax	-711.388	-
Withholding taxes	-	-607.932
Expense deferred taxes	-40.273	-1.984.751
Effective tax rate	24,45%	198%

*Applicable tax rate 2020: 16,5% over the taxable income until:	€ 200.000
*Applicable tax rate 2020: 25,0% over all further income above:	€ 200.000
*Applicable tax rate 2019: 19,0% over the taxable income until:	€ 200.000
*Applicable tax rate 2019: 25,0% over all further income above:	€ 200.000

#### 9.5 *Related parties*

All legal entities that can be controlled, jointly controlled or significantly influenced are considered to be a related party. The ultimate shareholder of the company is Evonik Industries AG, Essen (Germany). All companies in which Evonik Industries AG ultimately has a majority interest are considered to be a related party. Significant transactions in 2020 with related parties of Evonik Finance B.V. are disclosed in the notes 8.1, 8.3, 8.4, 8.7, 8.8, 8.11, 8.13, 8.15, 8.17 and 9.1.

Evonik International Holding B.V. provides management services to Evonik Finance B.V. In 2020, the cost of these management services amounted to €39.400 (2019: €38.435)

#### 9.6 *Average number of employees*

During 2020, 0 employees were employed on a full-time basis (2019: 0). In 2020 there was 1 employee employed for 0,1 FTE (2019: 0,1 FTE). Of these employees, 0 were employed outside the Netherlands (2019: 0). The average number of employees of proportionally consolidated companies was 0 in 2020 (2019: 0).

### 9.7 Director's remuneration

	2020	2019
	€	€
Current directors	13.584	13.452
	13.584	13.452

The total directors' remuneration is partly paid by Evonik Finance B.V. as salary and partly expenses by Evonik International Holding B.V. through the management fee as disclosed in note 9.5 Related parties. There are no other incentives for the directors.

### 9.8 Events after balance sheet date

No significant event has taken place after ending of the financial year, which would have substantial impact on these annual accounts, as per December 31, 2020.

Amsterdam, March 24, 2021

Laila Aoulad Si Kaddour  
Director

Alexander van der Weiden  
Director

Evonik Finance B.V.  
Hettenheувelweg 37  
1101 BM, Amsterdam

## OTHER INFORMATION

### Proposed appropriation of result

Following the profit appropriation proposed by the Management Board and pursuant to Article 18 sub 2 of the Articles of Association, the Management Board proposes to add the profit of €2.322.984 to the retained earnings reserves.

The management proposes the following appropriation of result:

	<u>2020</u>
	€
Addition to retained earnings reserve	2.322.984
Total addition to the retained earnings	<b>2.322.984</b>

This proposal, that is yet to be approved by the general meeting of shareholders, has already been taken into account in this annual statutory account.

The auditor's report is included on the next page.

## 8 INDEPENDENT AUDITOR'S REPORT



## *Independent auditor's report*

To: the general meeting of Evonik Finance B.V.

---

### *Report on the financial statements 2020*

---

#### *Our opinion*

In our opinion, the financial statements of Evonik Finance B.V. ('the Company') give a true and fair view of the financial position of the Company as at 31 December 2020, and of its result and its cash flows for the year then ended in accordance with Part 9 of Book 2 of the Dutch Civil Code.

#### *What we have audited*

We have audited the accompanying financial statements 2020 of Evonik Finance B.V., Amsterdam.

The financial statements comprise:

- the balance sheet as at 31 December 2020;
- the income statement for the year then ended;
- the cash flow statement for the year then ended; and
- the notes, comprising the accounting policies and other explanatory information.

The financial reporting framework applied in the preparation of the financial statements is Part 9 of Book 2 of the Dutch Civil Code.

---

#### *The basis for our opinion*

We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. We have further described our responsibilities under those standards in the section 'Our responsibilities for the audit of the financial statements' of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Independence*

We are independent of Evonik Finance B.V. in accordance with the European Union Regulation on specific requirements regarding statutory audit of public-interest entities, the 'Wet toezicht accountantsorganisaties' (Wta, Audit firms supervision act), the 'Verordening inzake de onafhankelijkheid van accountants bij assuranceopdrachten' (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore, we have complied with the 'Verordening gedrags- en beroepsregels accountants' (VGBA, Dutch Code of Ethics).

*KVPCY5JRUFHJ-371959126-14*

---

*PricewaterhouseCoopers Accountants N.V., Fascinatio Boulevard 350, 3065 WB Rotterdam, P.O. Box 8800, 3009 AV Rotterdam, the Netherlands*

*T: +31 (0) 88 792 00 10, F: +31 (0) 88 792 95 33, [www.pwc.nl](http://www.pwc.nl)*

'PwC' is the brand under which PricewaterhouseCoopers Accountants N.V. (Chamber of Commerce 34180285), PricewaterhouseCoopers Belastingadviseurs N.V. (Chamber of Commerce 34180284), PricewaterhouseCoopers Advisory N.V. (Chamber of Commerce 34180287), PricewaterhouseCoopers Compliance Services B.V. (Chamber of Commerce 51414406), PricewaterhouseCoopers Pensions, Actuarial & Insurance Services B.V. (Chamber of Commerce 54226368), PricewaterhouseCoopers B.V. (Chamber of Commerce 34180289) and other companies operate and provide services. These services are governed by General Terms and Conditions ('algemene voorwaarden'), which include provisions regarding our liability. Purchases by these companies are governed by General Terms and Conditions of Purchase ('algemene inkoopvoorwaarden'). At [www.pwc.nl](http://www.pwc.nl) more detailed information on these companies is available, including these General Terms and Conditions and the General Terms and Conditions of Purchase, which have also been filed at the Amsterdam Chamber of Commerce.



---

## ***Our audit approach***

### ***Overview and context***

The Company's main activity is the financing of group companies, through bond offerings on the international capital markets. The repayment of the bonds to the investors is guaranteed by Evonik Industries AG as disclosed in note 4.1 to the financial statements. The Company has derivative financial instruments in place to mitigate interest rate risk and currency risk. We paid specific attention to the areas of focus driven by the operations of the Company, as set out below.

As part of designing our audit, we determined materiality and assessed the risks of material misstatement in the financial statements. In particular, we considered where the board of directors made important judgements, for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. In note 4.7 of the financial statements the Company describes the areas of judgement in applying accounting policies and the key sources of estimation uncertainty. Given the significant estimation uncertainty and the related higher inherent risks of material misstatement in the valuation of derivatives and valuation of the loans to group companies, we considered these matters as key audit matters as set out in the section 'Key audit matters' of this report. Furthermore, we identified the existence of the loans to group companies as key audit matter because the importance of existence for users of the financial statements.

As in all of our audits, we also addressed the risk of management override of internal controls, including evaluating whether there was evidence of bias by the board of directors that may represent a risk of material misstatement due to fraud.

We ensured that the audit team included the appropriate skills and competences, which are needed for the audit of a finance company. We therefore included specialists in the area of valuation in our team.

### ***Materiality***

The scope of our audit is influenced by the application of materiality, which is further explained in the section 'Our responsibilities for the audit of the financial statements'.

Based on our professional judgement we determined certain quantitative thresholds for materiality, including the overall materiality for the financial statements as a whole as set out below. These, together with qualitative considerations, helped us to determine the nature, timing and extent of our audit procedures on the individual financial statement line items and disclosures and to evaluate the effect of identified misstatements, both individually and in aggregate, on the financial statements as a whole and on our opinion.

Based on our professional judgement, we determined the materiality for the financial statements as a whole at €15,300,000 (2019: €21,519,000). As a basis for our judgement, we used 1% of total assets. We used total assets as the primary benchmark, a generally accepted auditing practice, based on our analysis of the common information needs of the stakeholders. Inherent to the nature of the Company's business, the amounts in the balance sheet are large in proportion to the income statement line items personnel expenses, other operating expenses and income tax expenses. Based on qualitative considerations we performed audit procedures on those income statement line items, applying a benchmark of 10% of the total of those expenses.



We also take misstatements and/or possible misstatements into account that, in our judgement, are material for qualitative reasons.

We agreed with the board of directors that we would report to them misstatements identified during our audit above €765,000 (2019: €1,000,000) as well as misstatements below that amount that, in our view, warranted reporting for qualitative reasons.

### *Key audit matters*

Key audit matters are those matters that, in our professional judgement, were of most significance in the audit of the financial statements. We have communicated the key audit matters to the board of directors. The key audit matters are not a comprehensive reflection of all matters identified by our audit and that we discussed. In this section, we described the key audit matters and included a summary of the audit procedures we performed on those matters.

We addressed the key audit matters in the context of our audit of the financial statements as a whole, and in forming our opinion thereon. We do not provide separate opinions on these matters or on specific elements of the financial statements. Any comment or observation we made on the results of our procedures should be read in this context.

Due to the nature of the Company, key audit matters do not change significantly year over year. As compared to last year there have been no changes in key audit matters.

<i>Key audit matter</i>	<i>How our audit addressed the matter</i>
<p><b><i>Valuation of the loans to group companies</i></b> <i>Notes 8.1 and 8.4</i></p> <p>We considered the valuation of the loans to group companies, as disclosed in notes 8.1 and 8.4 to the financial statements for a total amount of €998,541,385 (non-current) and €453,534,584 (current) to be a key audit matter. This is because the board of directors has to identify objective evidence of impairment, which is very important and judgemental. Furthermore, an impairment may have a material effect on the financial statements.</p> <p>The board of directors monitors the need for changes in the methods, significant assumptions or the data used in making the accounting estimate by monitoring key performance indicators that may indicate unexpected or inconsistent performance.</p> <p>The board of directors did not identify any objective evidence that a loan is impaired. As stated in Note 4.6 to the financial statements, the board of directors of the Company has assessed that the impact of COVID-19 has been limited on the Company, due to the sector in which the group operates.</p> <p>As disclosed in note 8.1 to the financial statements, the Company has not and has not been asked to grant any payment holidays on their loans to group companies.</p>	<p>We performed the following procedures to test the board of directors' assessment of possible loss events to support the valuation of the loans to Evonik group companies:</p> <ul style="list-style-type: none"><li>• We evaluated the financial position of the counterparties of loans to group companies and their ability to repay the notional and interest to the Company, by assessing observable data from rating agencies, developments in credit spreads, current financial data (such as recent financial information and cash flows) and other publicly available data and by discussing and obtaining information from the group auditor.</li><li>• We have assessed the board of directors' position on the impact of the COVID-19 pandemic on the financial position of the counterparties of the loans to group companies as part of our procedures.</li></ul> <p>We found the board of directors' assessment to be sufficiently rigorous. Our procedures as set out above did not indicate material differences.</p>

---

### **Key audit matter**

#### **Existence of the loans to group companies**

##### *Notes 8.1 and 8.4*

We considered the existence of the loans to group companies, as disclosed in notes 8.1 and 8.4 to the financial statements for a total amount of €998,541,385 (non-current) and €453,534,584 (current), to be a key audit matter. Significant auditor's attention is necessary because of the size of the loan portfolio and the importance of existence for users of the financial statements.

#### **Derivative valuation**

##### *Note 8.3*

We considered the fair value of the derivatives portfolio of €71,853,747 (positive) as disclosed in note 8.3 to the financial statements and used in the Company's hedge effectiveness testing to be a key audit matter. This is due to the nature of the portfolio that includes longer-dated interest rate swaps and cross-currency interest rate swaps. The board of directors monitors the need for changes in the methods, significant assumptions or the data used in making the accounting estimate by monitoring key performance indicators that may indicate unexpected or inconsistent performance. The market for these swaps is not fully liquid, and therefore valuation is a complex area.

### **How our audit addressed the matter**

We performed the following procedures to support the existence of the loans to Evonik group companies:

- We confirmed the existence of the loans with the counterparties integrally.
- We compared interest receipts with bank statements.

Based on the procedures as set out above, we found no material differences.

We performed the following procedures to support the valuation of derivatives:

- We tested the valuation of derivatives as well as the valuation of hedged items in hedge accounting relationships (when relevant) by testing the input of contracts.
- We reconciled the interest rate curves and other market data with independent sources.
- We assessed whether the models are in line with market practice.
- We also tested the mathematical accuracy of the models used and reconciled the outcome of the valuation system with the general ledger.

We found the board of directors' assumptions used in the valuation of derivatives to be reasonable and appropriate compared to market data and the chosen models to be in line with market practice. Based on the procedures as set out above we found no material differences.

---

## **Report on the other information included in the financial report**

In addition to the financial statements and our auditor's report thereon, the financial report contains other information that consists of:

- the directors' report; and
- the other information pursuant to Part 9 of Book 2 of the Dutch Civil Code.

Based on the procedures performed as set out below, we conclude that the other information:

- is consistent with the financial statements and does not contain material misstatements; and
- contains the information that is required by Part 9 of Book 2 of the Dutch Civil Code.

We have read the other information. Based on our knowledge and understanding obtained in our audit of the financial statements or otherwise, we have considered whether the other information contains material misstatements.



By performing our procedures, we comply with the requirements of Part 9 of Book 2 of the Dutch Civil Code and the Dutch Standard 720. The scope of such procedures was substantially less than the scope of those performed in our audit of the financial statements.

The board of directors is responsible for the preparation of the other information, including the directors' report and the other information in accordance with Part 9 of Book 2 of the Dutch Civil Code.

---

## ***Report on other legal and regulatory requirements***

---

### ***Our appointment***

We were appointed as auditors of Evonik Finance B.V. following the passing of a resolution by the shareholders at the annual meeting held in 2011. Our appointment has been renewed annually by shareholders representing a total period of uninterrupted engagement appointment of ten years.

### ***No prohibited non-audit services***

To the best of our knowledge and belief, we have not provided prohibited non-audit services as referred to in Article 5(1) of the European Regulation on specific requirements regarding statutory audit of public-interest entities.

### ***Services rendered***

The services, in addition to the audit, that we have provided to the Company, for the period to which our statutory audit relates, are disclosed in note 9.3 to the financial statements.

---

## ***Responsibilities for the financial statements and the audit***

---

### ***Responsibilities of the board of directors for the financial statements***

The board of directors is responsible for:

- the preparation and fair presentation of the financial statements in accordance with Part 9 of Book 2 of the Dutch Civil Code; and for
- such internal control as the board of directors determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

As part of the preparation of the financial statements, the board of directors is responsible for assessing the Company's ability to continue as a going concern. Based on the financial reporting framework mentioned, the board of directors should prepare the financial statements using the going concern basis of accounting unless the board of directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The board of directors should disclose events and circumstances that may cast significant doubt on the Company's ability to continue as a going concern in the financial statements.



---

### ***Our responsibilities for the audit of the financial statements***

Our responsibility is to plan and perform an audit engagement in a manner that allows us to obtain sufficient and appropriate audit evidence to provide a basis for our opinion. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high but not absolute level of assurance, which makes it possible that we may not detect all material misstatements. Misstatements may arise due to fraud or error. They are considered to be material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

Materiality affects the nature, timing and extent of our audit procedures and the evaluation of the effect of identified misstatements on our opinion.

A more detailed description of our responsibilities is set out in the appendix to our report.

Rotterdam, 24 March 2021  
PricewaterhouseCoopers Accountants N.V.

Original has been signed by M.P.A Corver RA

---

## ***Appendix to our auditor's report on the financial statements 2020 of Evonik Finance B.V.***

---

In addition to what is included in our auditor's report, we have further set out in this appendix our responsibilities for the audit of the financial statements and explained what an audit involves.

### ***The auditor's responsibilities for the audit of the financial statements***

We have exercised professional judgement and have maintained professional scepticism throughout the audit in accordance with Dutch Standards on Auditing, ethical requirements and independence requirements. Our audit consisted, among other things of the following:

- Identifying and assessing the risks of material misstatement of the financial statements, whether due to fraud or error, designing and performing audit procedures responsive to those risks, and obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the intentional override of internal control.
- Obtaining an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the board of directors.
- Concluding on the appropriateness of the board of directors' use of the going concern basis of accounting, and based on the audit evidence obtained, concluding whether a material uncertainty exists related to events and/or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report and are made in the context of our opinion on the financial statements as a whole. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluating the overall presentation, structure and content of the financial statements, including the disclosures, and evaluating whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the board of directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. In this respect, we also issue an additional report to the audit committee in accordance with Article 11 of the EU Regulation on specific requirements regarding statutory audit of public-interest entities. The information included in this additional report is consistent with our audit opinion in this auditor's report.

We provide the board of directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related actions taken to eliminate threats or safeguards applied.



From the matters communicated with the board of directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, not communicating the matter is in the public interest.